Skip to main content
PATRYS LIMITED logo

PATRYS LIMITED — Investor Relations & Filings

Ticker · PAB ISIN · AU000000PAB9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 916 across all filing types
Latest filing 2024-10-13 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PAB

About PATRYS LIMITED

https://patrys.com/

Patrys Limited is a biotechnology company focused on the development of novel antibody-based therapies for the treatment of cancer. The company's primary platform is based on Deoxymabs, a suite of antibodies derived from the 3E10 lupus autoantibody. These antibodies possess the unique capability to cross cell membranes and the blood-brain barrier, targeting the cell nucleus to inhibit DNA damage repair mechanisms. Patrys' lead candidates, PAT-DX1 and PAT-DX3, are engineered to exploit the DNA repair deficiencies inherent in many cancer cells, particularly aggressive forms such as glioblastoma and triple-negative breast cancer. Beyond direct anti-tumor activity, the Deoxymab platform is designed for use in synthetic lethality applications and as a delivery vehicle for therapeutic payloads, including nanoparticles and imaging agents, to target primary and metastatic tumors.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - PAB 4 pages 14.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse or cessation of certain securities (options) for Patrys Limited. It includes specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an official announcement related to changes in the company's capital structure, specifically the cessation of securities. It is not a full financial report, earnings release, or management discussion. Given the nature of the content—notification of securities ceasing—it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes including cessation or lapse of securities.
2024-10-13 English
PAT-DX1 clinical development update 3 pages 320.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release from Patrys Limited providing an update on the clinical development of their therapeutic antibody PAT-DX1 and PAT-DX3. It discusses manufacturing challenges, strategic shifts in development focus, and invites investors to a webinar for further discussion. The content is an announcement of clinical development progress and company plans, not a detailed financial report, earnings release, or regulatory filing. It is a communication aimed at investors and the public to update on company activities and upcoming investor engagement. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to development progress and strategic direction impacting company value and investor relations.
2024-10-01 English
PAT-DX1 GMP specification testing update 2 pages 228.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX & Media Release providing an update on the GMP specification testing timeline for a drug substance (PAT-DX1) by Patrys Limited. It discusses delays in testing and the impact on clinical trial commencement. There are no financial statements, regulatory certifications, voting results, or detailed financial data. The document is a company announcement about operational progress and timelines, typical of a Capital/Financing Update or general corporate update. It is not an Annual Report, Earnings Release, or any detailed financial report. Given the nature of the update on manufacturing and clinical trial progress, the best fitting category is Capital/Financing Update (CAP). The document length is 4617 characters, which is consistent with a brief update rather than a full report.
2024-09-19 English
PAT-DX1 GMP specification testing update 2 pages 228.4KB
Capital/Financing Update Classification · 90% confidence The document is an ASX & Media Release providing an update on the GMP specification testing timeline for a drug substance (PAT-DX1) by Patrys Limited. It discusses delays in testing and the impact on clinical trial commencement. There are no financial statements, regulatory certifications, voting results, or detailed financial data. The document is a company announcement about operational progress and timelines, typical of a Capital/Financing Update or general corporate update. Given the content focuses on manufacturing and clinical development progress rather than fundraising or capital structure changes, but still is a corporate update on a key development milestone, the best fitting category is Capital/Financing Update (CAP). The document length is 4607 characters, which is short and consistent with a release rather than a full report. Therefore, the classification is CAP with high confidence.
2024-08-28 English
Appendix 4E and 2024 Annual Report 72 pages 14.8MB
Annual Report Classification · 100% confidence The document is titled 'Patrys Limited Appendix 4E Preliminary final report' and covers the financial year ended 30 June 2024. It includes detailed financial results such as loss after tax, net tangible assets, and cash position. It also contains extensive sections typical of an annual report, including Chairman's letter, Board of Directors and Management details, scientific overview, and a full table of contents listing financial statements and auditor's report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of audited financial statements and comprehensive company information confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document is classified as an Annual Report (10-K equivalent). FY 2024
2024-08-22 English
Appendix 4G and Corporate Governance Statement 28 pages 926.2KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed form used by ASX-listed entities to confirm compliance with corporate governance disclosure requirements. The document includes a key to where governance disclosures can be found, and it explicitly states it is not a substitute for the corporate governance statement itself. The document is a regulatory filing required to be lodged with ASX alongside the annual report but is not the annual report or the corporate governance statement itself. It is a compliance and verification tool related to governance disclosures, fitting the category of Regulatory Filings (RNS) as it does not contain financial statements or management discussion but is a regulatory compliance document.
2024-08-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.